The assessment of the role of PSMA-RLT in advanced salivary gland cancer has resulted in two clinical trials, the Early Phase 1 trial by “Peking Union Medical College Hospital” selected only adenoid cystic carcinoma (ACC) (NCT04801264), which led to the publication of the above-mentioned pilot study in 2022 [33], and the “Radboud University Medical Center” Phase 2 study completed in February 2023 with two different cohorts, including subjects with ACC and patients with salivary duct carcinoma (SDC) (NCT04291300–LUPSA). The gene discussed is FOLH1; the disease is adrenal cortex carcinoma.